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Cancer cells generate reactive oxygen species (ROS) resulting frommitochondrial dysfunction, stimulation of oncogenes, abnormal
metabolism, and aggravated inflammatory activities. Available evidence also suggests that cancer cells depend on intrinsic ROS
level for proliferation and survival. Both physiological and pathophysiological roles have been ascribed to ROS which cause lipid
peroxidation. In spite of their injurious effects, the ROS and the resulting lipid peroxidation products could be beneficial in cancer
treatment.This reviewpresents research findings suggesting that ROS and the resulting lipid peroxidation products could be utilized
to inhibit cancer growth or induce cancer cell death. It also underscores the potential of lipid peroxidation products to potentiate
the antitumor effect of other anticancer agents. The review also highlights evidence demonstrating other potential applications of
lipid peroxidation products in cancer treatment. These include the prospect of lipid peroxidation products as a diagnostic tool to
predict the chances of cancer recurrence, to monitor treatment progress or how well cancer patients respond to therapy. Further
and detailed research is required on how best to successfully, effectively, and selectively target cancer cells in humans using lipid
peroxidation products. This may prove to be an important strategy to complement current treatment regimens for cancer patients.
1. Introduction
The physiological and pathophysiological roles of ROS have
been a subject of research interests in the last few decades.
Due to their short half-lives, quantification of ROS (either
in vivo or in vitro) is a very challenging task. Consequently,
the oxidation products of ROS in biological samples are of
great interest because they are more stable and reflect the
magnitude of oxidative stress [1]. One of such oxidation prod-
ucts is lipid peroxidation products which are formed when
ROS attack polyunsaturated fatty acids (PUFAs) leading to
membrane structural and/or functional damage [2]. Lipid
peroxidation gives rise to the formation of highly reactive
aldehydes which are extremely diffusible and attack or form
covalent links with distant cellular components/targets [3].
Once ensued, lipid peroxidation is capable of self-propagating
and initiating chain reactions [4]. Inmost cases, the reactions
continue except they are terminated (e.g., by intervention
with antioxidants such as vitamin E) or there is complete
substrate utilization. Among the common lipid peroxidation
products are malondialdehyde (MDA), 4-hydroxynonenal
(HNE), and acrolein [5]. Others include isoprostanes (IsoPs)
and neuroprostanes (neuroPs), which are oxidized products
of arachidonic acid and docosahexaenoic acid, respectively
[6]. These lipid peroxidation products covalently bind to his-
tidine, cysteine, or lysine residues of protein throughMichael
addition resulting in structural alteration and impaired func-
tions of these protein residues [7]. These aldehydes in turn
propagate further attack on cellular membrane constituents,
primarily lipids and proteins, to generate other end prod-
ucts of lipid peroxidation commonly known as lipofuscin-
like pigments (LFPs) [8]. The role of lipid peroxidation
is implicated in the pathophysiology of or associated with
many chronic diseases such as Alzheimer’s disease, diabetes
mellitus, hypertension, and cancers in both animals and
humans [9–12]. In spite of the detrimental biological effects of
lipid peroxidation, this review presents evidence that suggests
lipid peroxidation products could be utilized in the treatment
of cancer.
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2. Lipid Peroxidation Products
2.1. Malondialdehyde. Malondialdehyde is a highly reactive
and toxic aldehyde formed as a consequence of peroxidation
of PUFAs. MDA can also be produced from the breakdown
of prostaglandin via the action of cyclooxygenase [13]. Other
nonlipid precursors including carbohydrates and amino acids
can also generate MDA [14]. Accumulation of MDA can
alter the membrane permeability as well as impair fluidity
of the membrane lipid bilayer [15]. MDA remains one of
the most mutagenic lipid peroxidation products. It can react
with deoxyadenosine and deoxyguanosine in DNA leading
to the development of DNA adducts which are mutagenic
[16, 17]. Malondialdehyde is a commonly used biomarker for
the assessment of lipid peroxidation [18].
2.2. 4-Hydroxy-2-nonenal. 4-Hydroxy-2-nonenal is a prod-
uct generated following peroxidation of n-6 polyunsaturated
fatty acids such as linoleic acid. Of all the aldehydes formed
from the lipid peroxidation of PUFAs, HNE is considered the
most important [19]. HNE, via Michael addition, is able to
bind to cysteine, lysine, and histidine residues of proteins.
These HNE-bound protein residues can impair normal pro-
tein structure and function [20]. HNE also reacts with many
important cellular constituents such as nucleic acids, lipids,
and vitamins as well as signaling molecules [21]. Such HNE
interactions can interfere with normal cellular functions such
as impaired glucose uptake at synapses and contributes to
synaptic degeneration [22]. It can also cause loss of organelle
functions such as microtubule dysfunction [23]. With these
effects, accumulation of HNE can exert harmful effects on
cellular functions and signaling and thereby elicit a number
of pathological states including neurodegenerative disorders
and cancers.
2.3. Acrolein. Acrolein is also one of the lipid peroxidation
products of PUFAs. It is the most reactive of all the lipid
peroxidation products [21]. In addition to PUFAs, it can be
produced from partial burning of organic materials or fuel
such as coal, petrol, and wood. It is also present in most
types of smokes including cigarette smoke. Other sources of
acrolein include cyclophosphamide bioactivation, threonine
metabolism bymyeloperoxidase of activated phagocytes, and
overheated frying oils [5, 24]. Like HNE and MDA, acrolein
is an electrophilic compound which rapidly interacts with
or binds to key cellular nucleophiles and enzymes resulting
in their depletion or inactivation [25]. It also reacts with
nucleophilic sites in proteins and DNA, an important mech-
anism by which it exerts its cytotoxicity. Acrolein induces cell
death, deterioration of cognitive function, and degeneration
of hippocampal neurons, suggestive of its significant role in
the pathophysiology of neurodegenerative diseases [26].
2.4. Isoprostanes. The isoprostanes, discovered in 1990, con-
stitute a family of prostaglandin-like compounds formed as
a consequence of free radical-induced oxidation of arachi-
donic acid (independently of cyclooxygenase) and later
liberated from membrane phospholipids by phospholipases
[27]. Compared to other lipid peroxidation products, IsoPs
are more easily detected and chemically and metabolically
stable in several biological samples such as urine, plasma,
and tissues [28]. Accumulation of IsoPs can impair integrity,
fluidity, and normal functions of membrane and is also
associated with many pathophysiological disorders [29]. F2-
IsoPs are among the well-researched IsoPs and considered
better biomarkers of endogenous lipid peroxidation [30].
The measurement of F2-IsoPs is considered one of the most
precise methods to evaluate oxidative stress and lipid perox-
idative damage in vivo [28, 31]. Conversely, its use may be
restricted in certain conditions with elevated concentrations
of oxygen which suppress the formation of IsoPs [32].
2.5. Isofurans. Isofurans (IsoFs) belong to a class of com-
pounds formed as a result of free radical-induced peroxida-
tion of arachidonic acid. Similar to IsoPs, IsoFs are stable
products, both chemically and metabolically [33]. However,
unlike the IsoPs which are generated under low oxygen
tension, the formation of IsoFs occurs or is favored at high
oxygen concentrations [32, 34].Therefore, isoFsmay likely be
important markers of oxidative stress in the brain as a result
of its high oxygen consumption potential. As a result of the
differences in oxygen tension required for the generation of
IsoPs and IsoFs, concurrent quantification of both IsoPs and
IsoFs is considered a better approach to evaluate oxidative
damage in disorders or conditions with varying concentra-
tions of oxygen such as anesthesia or surgery [35].
2.6. Neuroprostanes. The neuroprostanes (NeuroPs), also
known as F4-isoprostanes, are products of free radical-
catalyzed oxidation of docosahexaenoic acid (DHA). As a
result of the elevated concentrations of DHA in neuronal
membranes, neuroPs are regarded as important biomarkers
for quantitative assessment of oxidative damage in neurons,
cerebrospinal fluid, and brain tissues [36].
3. Cancer and Lipid Peroxidation Products
The incidence of and deaths due to cancers have risen vastly in
the past years. These have been attributed to several factors.
For instance, the global prevalence of lung cancer, which is
the most predominant type of cancer, has been on the rise
following increased worldwide cigarette smoking [37]. Other
common factors linked to the increased cancer incidence and
deaths include lifestyle patterns (such as physical inactivity,
obesity, and alcohol consumption) and genetic disposition
[38]. Research has linked ROS to the pathogenesis of many
chronic diseases including cancers. While elevated levels are
detrimental, moderate levels of ROS can be beneficial by
serving as a second messenger in cell signaling [39]. It is,
therefore, important to maintain redox homeostasis. The
mechanisms of increased ROS formation in cancer remain
poorly understood.Mitochondrial mutations or dysfunction,
which are frequently observed in cancer patients, may play a
role [40, 41]. Increased ROS formation due to mitochondrial
mutations is caused by impaired electron transfer which
results in leakage of electrons and subsequent generation
of superoxide radical and other ROS [42]. Other factors
implicated in the increased formation of ROS in cancer
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cells include oncogenic initiation, abnormal metabolism, and
enhanced activity of inflammatory cytokines [43, 44].
Many forms of cancers are associated with enhanced
ROSproduction resulting in lipid peroxidation. PlasmaMDA
levels have been found to be considerably higher in patients
with lung cancer [45], breast cancer [46], colorectal cancer
[47], and prostate cancer [48] than in healthy controls.
Increased MDA levels have also been reported in patients
with other forms of cancers such as laryngeal, oral cavity, and
gastrointestinal tract cancers [49, 50]. BesidesMDA, elevated
levels of urinary IsoPs have been associated with breast or
lung cancer risk [51]. Urinary IsoPs excretion was observed
to bemarkedly higher in patients with prostate cancer than in
the controls [52]. A similar increase in urinary IsoPs excretion
was reported in gastric cancer patients [53].These data clearly
indicate that lipid peroxidation products are elevated in most
forms of cancers and implicate the role of lipid peroxidation
products in the etiology or progression of cancers.
4. Lipid Peroxidation Products and
Cancer Growth Inhibition
Polyunsaturated fatty acids (PUFAs) of cell membrane are
highly susceptible to lipid peroxidation. Hence, incorpo-
rating or increasing the PUFAs content of cancer cells
may predispose these cells to enhanced lipid peroxidation.
Besides, PUFAs in combination with anticancer agents such
as doxorubicin and arsenic trioxide have been shown to
elicit synergistic cytotoxic effect in various cancer cells such
as breast, colon, cervical, pancreatic, and renal cancer cells
[54–56]. A recent study showed that PUFAs augmented the
sensitivity and cell death of leukemic cells to anticancer
agents such as doxorubicin, vincristine, and fludarabine [57].
In addition to enhancing the antitumor effect of anticancer
drugs, lipid peroxidation products may also be used as an
adjunct in radiotherapy. A study found that omega-3 PUFAs
enhanced the sensitivity of human colorectal adenocarci-
noma cells to radiation in a dose-dependent manner [58].
In all these studies, increased cytotoxicity was mediated
via enhanced formation of lipid peroxidation products such
as MDA and ROS or via markedly reduced intracellular
concentrations of glutathione and activity of glutathione
S-transferase (an important enzyme that scavenges lipid
peroxidation products) in cancer cells [57, 58]. This syner-
gistic effect was markedly inhibited by antioxidants or lipid
peroxidation inhibitors, such as N-acetylcysteine, lipoic acid,
and 𝛼-tocopherol, and thereby corroborate the role of lipid
peroxidation products [54–56].
Of late, reports indicate that lipid peroxidation prod-
ucts may serve as a therapeutic tool to induce death of
proliferating tumor cells. In one of such studies, acrolein
was found to exert cytotoxic effect in lung carcinoma and
glioblastoma cells. This cytotoxicity was suppressed by lipid
peroxidation inhibitors or antioxidants such as vitamin E,
ebselen (a glutathione peroxidase mimic), and selenite [59].
In addition to its inhibiting effect on cancer growth, lipid
peroxidation products in combination with antitumor agents
or cancer therapy may exert additive or synergistic effect.
Acrolein combined with TNF-related apoptosis-inducing
ligand (TRAIL) potentiates TRAIL-induced apoptosis via
downregulation of Bcl-2 expression and ROS-dependent
upregulation of TRAIL death receptor 5 in human renal
cancer cells [60]. Similarly,HNE in combinationwith panobi-
nostat, a histone deacetylase inhibitor (HDACI), exerts
greater inhibition of PC3 prostate cancer cell proliferation.
The combination also induces greater G2/M arrest, DNA
damage, and cell death in prostate cancer cells [61]. These
findings reveal that lipid peroxidation products have anti-
tumor activity and can also potentiate the cytotoxicity of
anticancer agents and radiotherapy. Recent studies indicating
that many investigational antitumor agents (such as elesclo-
mol, costunolide, and deltonin) exert their anticancer effect
via selective mitochondrial ROS induction in cancer cells
provide additional evidence in support of the potential role of
lipid peroxidation products in cancer growth inhibition [62–
64].
Thepotential role of lipid peroxidation products in cancer
growth inhibition has also been demonstrated in rodents.
A study which investigated the effect of diets comprising
varied amounts and types of fat in female athymic nude mice
implanted with human breast carcinoma cells found that the
mice fed fish oil diets had markedly lower mean volume of
human breast carcinoma than those fed corn oil diets [65].
It was also observed that tumor lipid peroxidation product
levels were significantly increased only in the fish oil diets-
fed mice [65]. These data suggest that the reduced breast
carcinoma volume observed in mice fed fish oil diets could
be attributed to elevated levels of tumor lipid peroxidation
products in the same mice. Addition of antioxidants to
the fish oil diets significantly decreased the level of tumor
peroxidation products and increased tumor volume. On the
other hand, addition of ferric citrate (a potent inducer of
lipid peroxidation) to the fish oil diets resulted in markedly
increased levels of tumor lipid peroxidation products as
well as diminished tumor volume [65]. Similarly, dietary
fish oil supplementation in athymic mice implanted with
MX-1 human mammary carcinoma was accompanied by
tumor growth inhibition as well as increased tumor lipid
peroxidation and protein oxidation products [66].These data
convincingly indicate that dietary fish oil inhibits the growth
of breast carcinoma in nude mice via increased formation of
tumor lipid peroxidation products.
In nude mice implanted with DLD-1 human colon cancer
cells, 𝛼-eleostearic acid (𝛼-ESA) supplementation induced
apoptosis (enhanced DNA fragmentation) via increased for-
mation of lipid peroxidation products [67].The addition of an
antioxidant led to suppression of lipid peroxidation products
and apoptosis, indicating that the antitumor effect of 𝛼-ESA
is mediated via accumulation of lipid peroxidation products
[67]. A recent study also provides further evidence in support
of the antitumor effect of lipid peroxidation product (HNE)
in rodents. The authors found that blockade of mercapturic
acid pathway-mediated elimination of HNE resulted in total
remission of human cancer xenografts in nude mice [68].
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Table 1: A summary of the effect of lipid peroxidation products (alone or in combination with cancer therapy) on cancer cells.
Type of cancer or
tumor cells
Lipid peroxidation
products Summary of key findings Reference








Acrolein Inhibition of tumor growth [59]
Renal cancer cells Acrolein Potentiation of TRAIL-induced apoptosis; downregulated expression of Bcl-2;ROS dependent upregulation of TRAIL death receptor 5 [60]
Prostate cancer
cells HNE
Potentiation of inhibiting effect of panobinostat; augmented G2/M arrest;




MDA Inhibition of tumor growth [65, 66]
Colon cancer cells MDA Increased DNA fragmentation; induction of apoptosis [67]
Neuroblastoma
cells HNE
Inhibition of cell proliferation; reduction of S-phase cells; induction of





Inhibition of cell proliferation; downregulation of TERT expression and
telomerase activity; inhibition of c-Myc expression; activation of Mad-1
expression; interference with DNA binding activity of c-Myc and Mad-1 to
TERT promoter
[80, 81]
MDA: malondialdehyde; HNE: 4-hydroxynonenal; ROS: reactive oxygen species; TERT: telomerase reverse transcriptase; TRAIL: TNF-related apoptosis-
inducing ligand.
5. Other Potential Applications of Lipid
Peroxidation Products in Cancer Treatment
In addition to its inhibitory effect on cancer growth, available
evidence suggests that the levels of lipid peroxidation prod-
ucts may reflect cancer severity. In patients with carcinoma
of the oral cavity and oropharynx, it was found that MDA
levels in patients with T3-4 tumors were markedly higher
than in those with T1-2 cancers [69]. The authors also found
that patients who exhibited recurrence had significantly
higher MDA levels than those with complete remission [69].
Similarly, Chole and colleagues found that serum MDA
levels in patients with oral precancer were much lower
than in those with oral cancer, and it was observed to be
the lowest in the controls [70]. Increasing levels of lipid
peroxidation biomarkers including MDA and HNE have
also been observed in patients suffering from other types
of cancers (such as myeloid leukaemia, gastric, and breast
cancers) as the disease progressed [71–73]. Lipid peroxidation
products, therefore, could serve as a marker of initial stages
of tumor development, progression, and metastasis as well as
predicting the chances of cancer relapse.
The levels of oxidative stress markers such as lipid perox-
idation products may also reveal the effectiveness of cancer
therapy or surgical intervention. Reduced MDA levels have
been demonstrated postoperatively in lung cancer patients
following removal of cancer-associated parenchyma [74]. A
similar finding (significantly reduced MDA levels) has also
been reported in surgically treated colorectal cancer patients
(both early and advanced stages) [75]. Hence, these findings
suggest that, by comparing data obtained before and after
cancer treatment, the levels of lipid peroxidation products
could be used to monitor the progress and/or evaluate the
effectiveness of therapy or surgery in patients with cancers.
6. Potential Mechanisms of Cancer Growth
Inhibition by Lipid Peroxidation Products
In the last few years, the roles of several transcription factors
have been implicated in the development of cancers. The p53
is a transcription factor which prevents free radical-induced
gene mutations by detecting and getting rid of oxidatively
damaged DNA [76]. Upon stimulation, p53 also induces a
host of other genes which in turn cause cell cycle arrest
and apoptosis [76, 77]. The loss of function of p53 family
is known to contribute to cancer progression. In human
neuroblastoma cell lines, HNE has been shown to inhibit
proliferation, reduce S-phase cells, and induce apoptosis via
upregulated expression of p53 tumor suppressor and target
proteins [78].
The telomerase and telomerase reverse transcriptase
(TERT) constitute an essential component of the telomerase
complex which role is also implicated in the etiology and
progression of cancer. Telomerase catalyzes the elongation
of telomeres in DNA strands with the aid of telomerase
complex [79]. This enzyme, therefore, plays an essential role
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in the transformation of senescent cells to potentially nonse-
nescent or immortal cells, which is of significant importance
in tumorigenesis. HNE has been found to downregulate the
expression and activity of TERT and telomerase, respectively,
in human leukemic cell lines [80]. Similar to inhibitory effect
of HNE on telomerase activity, downregulation of TERT
expression and inhibition of cell proliferation have also been
observed in colon carcinoma cells [81].
Besides inhibiting telomerase complex, lipid peroxidation
products may modulate the expression of c-Myc/Mad/Max
network. The c-Myc/Mad/Max network consists of tran-
scription factors which interactions elicit activation or sup-
pression of specific or target genes involved in cell-cycle
progression, genomic instability, and tumor progression and
expansion [82, 83]. For instance, the c-Mycwhich can activate
telomerase complex (telomerase and TERT) is overexpressed
in many forms of cancers [84]. The c-Myc also induces
DNA damage and attenuates p53 function [85]. HNE has
been shown to inhibit c-Myc expression while it upregulates
Mad-1 expression. HNE also interferes with theDNAbinding
activity of c-Myc and Mad-1 to the hTERT promoter [80].
The ability of lipid peroxidation products such as HNE to
modulate a number of transcription factors known to play
vital roles in the pathophysiology or progression of cancer
may be one of the mechanisms of its cytotoxicity in cancer
cells.The summary of the effect of lipid peroxidation products
on cancer cells is presented in Table 1.
7. Conclusions
There is no doubt that ROS and lipid peroxidation play a role
in cancer development. However, evidence also indicates that
cancer cells require certain amounts of ROS for proliferation
and survival. This, therefore, suggests strategies aimed at
further increasing the levels of ROS and oxidative damage
such as lipid peroxidation products may be deleterious to
cancer cells and thus beneficial in cancer management. As
highlighted in this review, compelling evidence shows that
lipid peroxidation products exert antitumor effect and also
potentiate the cytotoxicity of anticancer drugs and radio-
therapy. Lipid peroxidation biomarkers could also serve as a
diagnostic tool to predict the chances of cancer recurrence
and be used to monitor the progress or effectiveness of
therapy in cancer patients. The findings also reveal insights
into the possible molecular mechanisms (via modulation
of key cancer-related transcription factors) by which lipid
peroxidation products may inhibit or suppress the growth
of cancers. Selectively enhanced ROS formation and its
suppressed elimination remain key viable options in explor-
ing lipid peroxidation-mediated cancer cell death. At the
moment, as a result of the double-edged sword property of
ROS, one of the main challenges is how best to successfully,
effectively, and selectively target cancer cells in humans using
lipid peroxidation products. This is an area that requires
further and detailed research as it may prove to be an impor-
tant strategy to complement current treatment regimens for
cancer patients.
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